Novartis Posts Strong 2025 Results and Pipeline Wins as It Enters Major Patent-Expiry Year
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novartis ( (NVS) ) just unveiled an announcement.
On February 4, 2026, Novartis reported its financial results for the fourth quarter and full year 2025, highlighting robust full-year performance despite mounting US generic competition. For 2025, net sales rose 8% to USD 54.5 billion with core operating income up 14% at constant currencies and a core operating margin of 40.1%, driven by strong growth in priority brands such as Kisqali, Kesimpta, Pluvicto, Scemblix and Cosentyx, while operating income climbed 25% at constant currencies and net income increased 19%. Free cash flow for the year reached USD 17.6 billion, up 8%, underpinning a proposed 5.7% dividend increase to CHF 3.70 per share for 2025. In the fourth quarter of 2025, net sales were broadly flat at USD 13.3 billion (-1% in constant currencies) as volume gains were offset by generic erosion and US revenue-deduction adjustments, but core operating income still edged higher and key growth brands maintained strong double‑digit momentum. The company also reported multiple late‑stage pipeline advances and regulatory milestones in the quarter, including FDA approval of Itvisma for a broad spinal muscular atrophy population, European approval of Scemblix for newly diagnosed Ph+ chronic myeloid leukemia, and FDA submissions for remibrutinib in chronic inducible urticaria and Pluvicto in an earlier prostate cancer setting. Management emphasized that this performance, combined with strategic pipeline deals such as the planned acquisition of Avidity and solid cash generation, positions Novartis to navigate what it describes as the largest patent expiry in its history in 2026 while remaining on track with its mid‑term financial ambitions.
The most recent analyst rating on (NVS) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.
Spark’s Take on NVS Stock
According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.
Novartis presents a strong investment case with robust financial performance and positive earnings call highlights. The technical analysis supports a positive trend, though valuation metrics are moderate. The company’s strategic focus on innovation and expansion, despite some market challenges, underpins its growth potential.
To see Spark’s full report on NVS stock, click here.
More about Novartis
Novartis AG is a Switzerland-based “pure-play” innovative medicines company focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology. It markets a portfolio of significant in-market brands, including blockbuster therapies such as Cosentyx, Kisqali, Kesimpta, Pluvicto and Scemblix, and is investing heavily in emerging technology platforms including gene and cell therapy, radioligand therapy and xRNA, while targeting growth in key geographies such as the US, China, Germany and Japan.
Average Trading Volume: 1,667,903
Technical Sentiment Signal: Buy
Current Market Cap: $287.7B
See more insights into NVS stock on TipRanks’ Stock Analysis page.
